Journal of Medical Physics
 Home | Search | Ahead of print | Current Issue | Archives | Instructions | Subscription | Login  The official journal of AMPI, IOMP and AFOMP      
 Users online: 483  Home  EMail this page Print this page Decrease font size Default font size Increase font size 


 
 Table of Contents    
ORIGINAL ARTICLE
Year : 2022  |  Volume : 47  |  Issue : 2  |  Page : 194-200
 

Human absorbed dose estimation of 111In-DOTA-PR81 as a novel high potential agent for breast cancer imaging


Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran

Date of Submission17-May-2021
Date of Decision01-Feb-2022
Date of Acceptance08-Feb-2022
Date of Web Publication5-Aug-2022

Correspondence Address:
Dr. Behrouz Alirezapour
Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jmp.jmp_72_21

Rights and Permissions

 

   Abstract 

Purpose: In this study, the human absorbed dose of 111In-DOTA-PR81 as a new radioimmunoconjugate for single-photon emission computed tomography (SPECT) imaging of MUC1 + breast cancer was determined. Materials and Methods: The complex was prepared at optimized conditions in about 1 h and 38°C. The radiochemical purity of the tracer was investigated using the instant thin-layer chromatography method method, showing purity of higher than 96%. After evaluating the stability of the product in human serum and room temperature, the biological distribution of the radiolabeled compound was studied in normal rats and tumor-bearing mice. Finally, the human absorbed dose of the complex was estimated based on animals' data using radiation dose assessment resource and Spark et al. methods. Results: High uptake of the complex in MUC1 + breast tumors compared to other nontarget organs shows that the radioimmunoconjugate is a beneficial agent for SPECT imaging of MUC1 + breast cancer. Human organs absorbed dose estimation of the complex demonstrated the highest amounts of the absorbed dose are in the liver and kidneys with 0.384 and 0.245 mGy/MBq, respectively. Conclusions: 111In-DOTA-PR81 radioimmunoconjugate is a high potential agent for MUC1 + breast cancer SPECT imaging and estimated absorbed dose values could helpfully use for the determination of the maximum injectable dose.


Keywords: Absorbed dose, anti-MUC1, breast cancer, indium-111, radiation dose assessment resource


How to cite this article:
Yousefnia H, Zolghadri S, Alirezapour B. Human absorbed dose estimation of 111In-DOTA-PR81 as a novel high potential agent for breast cancer imaging. J Med Phys 2022;47:194-200

How to cite this URL:
Yousefnia H, Zolghadri S, Alirezapour B. Human absorbed dose estimation of 111In-DOTA-PR81 as a novel high potential agent for breast cancer imaging. J Med Phys [serial online] 2022 [cited 2022 Aug 12];47:194-200. Available from: https://www.jmp.org.in/text.asp?2022/47/2/194/353330



   Introduction Top


The early diagnosis of high prevalence breast cancer is one of the most critical issues in treatment management. New diagnostic approaches such as radioimmunoscintigraphy (RIS) can take advantage of antibody specificity to tumor surface antigens as well as noninvasive emitted radiation from a radioisotope to the other nontarget organs.[1] MUC1, a transmembrane protein expressed on somatic cells of the secretory system, is overexpressed in the human breast ovary and other adenosarcomas[2],[3],[4] and can be a suitable target to detect this type of cancer.[4]

MUC1 is recognized by a series of antibodies, including PR81 which, was introduced by Paknejad et al.[3] PR81 and other monoclonal antibodies are the main category of molecules in targeted therapy of cancers. PR81 has high specific reactivity and also a high affinity to two peptides of TSA-P1-24 and A-P1-15.[3] While, PR81 labeled 99mTc indicated good efficiency, the complex suffered from low immunoreactivity and in vitro stability in human serum.[5]

111In, a cyclotron-produced radionuclide, is an exciting radioisotope to radiopharmaceutical goals because of its physical properties, easy production, and availability.[6] It emits gamma photons of 173 and 247 keV; 89% and 94% intensity, respectively. Conformity of 111In and the monoclonal antibodies biological half-life makes this radionuclide as a favorable option for single photon emission computed tomography (SPECT).[7],[8],[9] The SPECT results of 111In labeled bombesin, HIgG, DOTMP, and BPAMD show the usefulness of this radionuclide in the imaging detection process of SPECT.[6],[7],[8],[9],[10]

Radiation absorbed dose defined as the amount of energy deposited in a unit mass of any organs, plays a significant role in evaluating the risks associated with the administration of radiopharmaceuticals and also in determining the maximum amount of administrated activity.[11] After the development of the medical internal radiation absorbed dose method, as the primary method for calculating the absorbed dose, nowadays, some resources are available for this purpose. The radiation dose assessment resource (RADAR) is the most common source for the calculation of the absorbed dose.[12]

In this piece of research work, the human absorbed dose of 111In-DOTA-PR81, a newly developed RIS tracer, was estimated based on biodistribution studies in animals by the RADAR method. For this purpose, 111In-DOTA-PR81 was prepared in optimal condition and its radiochemical purity, and in vitro and in vivo stabilities were studied. The final radiolabeled compound was injected into normal rats and tumor-bearing mice, and the biodistribution of the radioimmunoconjugate was assessed at different intervals up to 72 h postinjection. Finally, the human absorbed dose of the radiotracer was estimated based on the gathered data in animals according to the standard methods.


   Materials and Methods Top


111In was produced in Radiation Application Research School, Karaj, Iran, by 112Cd (p, 2n) 111In reaction. DOTA-NHS was purchased from Macrocyclics (NJ, USA). Fetal Bovine Albumin, RPMI-1640 medium, and L-Glutamine were bought from Gibco Co. (Dublin, Ireland). PD10 De-salting column was inquired from Amersham Pharmacia Biotech; additional chemicals were purchased from Sigma Chemical Co. (MO, USA). Sprague-Dawley rats were obtained from Pasteur Institute (Tehran, Iran). A Bioscan AR-2000 radio thin-layer chromatography (TLC) scanner instrument (Bioscan, Paris, France) was used for Radio-chromatography purposes. A p-type coaxial high-purity germanium (HPGe) detector (model: EGPC 80–200R) coupled with a multichannel analyzer card system and a dose calibrator ISOMED 1010 (Dresden, Germany) were utilized for the measurement of the activity. Calculations were carried out based on the 245 keV peak for 111In. The United Kingdom Biological Council's Guidelines on the Use of the Living Animals in Scientific Investigations, 2nd edition was used to determine the framework of animal experiments. Achieved results are displayed as mean ± standard deviation (mean ± standard deviation), and Student's t-test was used to compare the data based on statistical significance defined as P < 0.05.

Production and quality control of 111InCl3

Indium-111 was produced according to the previously reported procedure.[13] Briefly, cadmium was electroplated on a copper surface to be used as a target and irradiated by a 22 megaelectron volt (MeV) proton at a 30 MeV cyclotron for 100 μAh to produce 111In. Indium-111 was eluted with 1 N Hydrochloric acid (HCl) (25 ml) as 111InCl3 for labeling use. Radionuclidic purity of the final solution was measured by the HPGe detector. Chemical purity control was carried out to ensure that the amounts of cadmium (from target material) and copper (from target support) ions in the final solution are acceptable regarding the internationally accepted limits. Chemical purity was studied by differential-pulsed anodic stripping polarography. The radiochemical purity of the 111InCl3 solution was also measured by the instant thin-layer chromatography method (ITLC) with two solvent systems, 1 mM diethylenetriaminepentaacetic acid (DTPA) and 10% ammonium acetate: methanol mixture.

Preparation and quality control of 111In-DTPA-PR81

DOTA-NHS was conjugated with the PR81 according to the previously published method.[14] For the preparation of 111In-DOTA-PR81 complex at optimized condition, 74 MBq of 111In-InCl3 (in 0.2 M HCl) was added to conical vials, and dried under a flow of nitrogen and gentle heating. Then, pH was arranged to 5.5 by ammonium acetate buffer. A total of 400 μg of the bioconjugate was added to the vial and the sample was taken for 1 h at 38°C. The radiolabeling step was terminated by adding ethylenediaminetetraacetic acid (EDTA) to their solution mentioned above, and it was allowed to react for 5 min. The addition of EDTA also resulted in the production of the In-EDTA complex, which makes it more applicable for better removal with the help of the size exclusion method. The radiochemical purity of the final product was studied by ITLC using a radio TLC scanner (Whatman no. 2; 1 mM DTPA).

Stability tests

About 18.5 MBq of the final radioimmunoconjugate was added to the Phosphate Buffered Saline (PBS) buffer and freshly prepared human serum while keeping at 4°C and 37°C, respectively. Samples were taken from the complex up to 72 h after preparation, and the stability of the final complex in PBS buffer and human serum was assessed by measuring radiochemical purity.

A mouse model with breast tumor

A few BALB/c mice with grade II/III invasive ductal carcinoma were provided from Pasteur Institute, Tehran, Iran. These mice breast tumor models were used for the development of the tumor allograft in other healthy BALB/c mice. The tumor was established by subcutaneous implantation of spontaneous breast tumor fragments (2–3 mm3) in the right side of the abdominal region (Flank) of inbred female BALB/c mice (16–25 g, 6–8 weeks old). The bio-distribution and imaging studies were performed when the tumor volume reached 70–80 mm3. All the animal experiments were approved by the Animal Care Committee of Tarbiat Modares University.

Biodistribution of 111In-DOTA-PR81 in normal and tumor-bearing animals

3.7 MBq of 111In-DOTA-PR81 was injected intravenously into Sprague-Dawley rats (140–160 g, 8–10 weeks' age) and tumoral BALB/c mice. It should be noted that while most studies in normal rodents are performed on normal rats, creating tumors in rats are very difficult and require difficult conditions. Therefore, for the study of tumoral cases, BALB/c mice was used to investigate the specialized uptake and accumulation of the labeled compound in the tumor containing the MUC1 receptor. The rats were sacrificed at 12, 24, 48, and 72 h postinjection (n = 4). Their organs, including blood, liver, spleen, kidneys, stomach, small and large intestines, heart, lungs, muscle, skin, bone, and tumor were taken, rinsed with normal saline, weighted, and their activity was measured by a p-type coaxial HPGe detector. The activity of each tissue was calculated using Equation 1:[15]



where ε is the efficiency at photopeak energy, γ is the emission probability of the gamma line corresponding to the peak energy, ts is the lifetime of the sample spectrum collection in seconds, m is the mass (kg) of the measured sample, k1, k2, k3, k4 and k5 are the correction factors for the nuclide decay from the time the sample is collected to start the measurement, the nuclide decay during the counting period, self-attenuation in the measured sample, pulses loss due to random summing and the coincidence, respectively. N is the corrected net peak area of the corresponding photopeak given as:



where Ns is the net peak area in the sample spectrum, Nb is the corresponding net peak area in the background spectrum, and tb is the lifetime of the background spectrum collection in seconds.

Accumulated activity calculation for animal organs

The nondecay corrected percentage of the injected activity versus time for different animal organs was plotted according to Equation 3.



where A (t) is the activity of each organ at time t.

To calculate the cumulative activity for each source organ, according to Equation 3, it is necessary to calculate the area under the time-activity curves in the time interval of Zero to infinity. For this purpose, two curves were plotted. The first curve was drawn based on the obtained data from the activity of each animal's organ and the second one was extrapolated to infinity by fitting the tail of each curve to a monoexponential curve with the exponential coefficient equal to the physical decay constant of the indium-111 radionuclide. Whereas the activity of blood at t = 0 was considered the total amount of the injected activity, the activity of all other organs was assumed to be zero at that time.

Estimation of accumulated activity for human organs

Sparks et al. method was used to scale the cumulated activity for animal organs to the cumulated activity for human organs (Equ 4).[16] The standard mean weights for each human organ were utilized for the extrapolation.[17]



Absorbed dose calculation

The absorbed dose in human organs, D, was calculated utilizing the RADAR formalism and based on biodistribution data in rats:



where A ̃is the accumulated activity for each human organ, and dose factor (DF) (in mGy = MBq s) represents the physical decay characteristics of the radionuclide, the range of the emitted radiations, and the organ size and configuration and defined as:



In this equation, ni is the number of radiations with energy E emitted per nuclear transition, Ei is the energy per radiation (MeV), ϕi is the fraction of energy emitted that is absorbed in the target, m is the mass of the target region (kg), and k is some proportionality constant . In this research, DFs presented in OLINDA/EXM software were employed.[18]

Calculation of effective absorbed dose

The effective absorbed dose was calculated using Equation 7.



where HT is the equivalent absorbed dose which is the product of the absorbed dose for each organ (D) and the radiation weighting factors and WT is the tissue-weighting factor that obtained from the reported value in International Commission On Radiological Protection (ICRP 103).[19]


   Results and Discussion Top


Quality control of 111In chloride solution

The HPGe spectrum of 111InCl3 showed the presence of 171 and 245 keV gamma energies, all originating from 111In. The radionuclidic purity of >99.9% was demonstrated. The result of polarography showed the concentrations of cadmium and copper were below the internationally accepted levels, i.e., 0.1 ppm.[20] The radiochemical purity of the 111InCl3 sample was more than 99% [Figure 1].
Figure 1: Instant thin-layer chromatography method chromatograms of 111InCl3 in Diethylenetriaminepentaacetic acid solution (a) and 10% ammonium acetate: methanol mixture (1:1) solution (b) using Whatman no. 2

Click here to view


Preparation and quality control of 111In-DOTA-PR81

111In-DOTA-PR81 was prepared with radiochemical purity of >96%at optimized conditions. ITLC chromatograms of 111In and 111In-DOTA-PR81 are indicated in [Figure 2]. While the free cation migrates to higher Rf (0.8), the radiolabeled compound remains at the origin [Figure 2].
Figure 2: Radiochromatogram of free 111In3+ (a) and 111In-DOTA-PR81 (b) using Whatman No. 2 in 1 mM DTPA pH 5.0 (n = 3)

Click here to view


Biodistribution of the complex in normal and tumor-bearing animals

The percentage of the injected dose per gram in animal organs was calculated up to 72 h after injection of 111In-DOTA-PR81. The nondecay corrected clearance curves from the main organ sources of the animals for the radiolabeled compound are shown in [Figure 3] that indicated high uptake of the tumor compared to other nontarget organs.
Figure 3: Non-decay corrected clearance curves of the animals' organs after injection of 111In-DOTA-PR81 complex

Click here to view


Equivalent absorbed dose calculation

In this study, human organ absorbed dose was estimated based on the animals' data which is a prerequisite in radiopharmaceutical development and is suggested in the ICRP 62 recommendations.[21],[22] For this purpose, RADAR and Spark et al. methods were utilized in similarity to the previously reported literature.[23],[24],[25]

In the calculation of the accumulated activity of each organ, two different approaches may be considered. In the first approach, before any decay correction, the measured %ID data are fitted with an appropriate curve. In this case, a linear extrapolation of the data points at 24 h, 48 h, and 72 h can be considered and all negative data resulting from the extrapolation are set to zero. In the case of the tumor, the data points at 24 h, 48 h, and 72 h may be fitted by a mono-exponential curve. Afterward the total curve (= measured and fitted part) are decay corrected and integrated until favorably 5 half-lives. In the second approach, it is assumed that the organ uptake remains constant after 72 h. In this way, the activity integral is calculated just by the time-activity curve of the radionuclide. The second approach may result in some overestimation of the integral. In this study, the second approach was considered for the calculation of the accumulated activity that leads to some overestimation of the absorbed doses. Thus, the actual absorbed doses are less. It seems an overestimation of the radiation dose is better than an underestimation in light of the safety aspect of the patient.

The values of residence time and the absorbed dose in different human organs are shown in [Table 1] and [Table 2], respectively. As seen, the highest amounts of the absorbed dose after injection of the radiolabeled compound was observed in the liver and kidneys with 0.384 and 0.245 mGy/MBq, respectively. Furthermore, the effective absorbed dose in humans after injection of 111In-DOTA-PR81 was estimated as 0.050 mGy/MBq.
Table 1: The residence time(s) calculated for human organs

Click here to view
Table 2: Equivalent and effective absorbed dose delivered into human organs after injection of 111In-DOTA-PR81

Click here to view


Different radiopharmaceuticals, including 18F-FES, 18F-FDHT, 111In-trastuzumab, and 111In-pentetreotide have been developed and used for breast cancer imaging.[26],[27],[28],[29] The values of the effective absorbed dose and the absorbed dose of critical organs (who received the highest amount) after injections of these radiolabeled compounds are presented in [Table 3].
Table 3: The values of the effective absorbed dose and the absorbed dose of organs received the highest dose after injection of 18F-FES, 18F-FDHT, 111In-trastuzumab, 111In-pentetreotide and 111In-DOTA-PR81

Click here to view


As can be seen, while the absorbed dose of critical organs and the effective absorbed dose after injection of 111In-DOTA-PR81 are significant compared to the other radiolabeled compounds of 18F, these amounts are lesser in contrast to the 111In-trastuzumab and 111In-pentetreotide. As a result, this new radiolabeled compound can be regarded as a safe complex and a suitable alternative for SPECT imaging of the MUC1 + breast tumors; however, further studies are still needed.


   Conclusions Top


In this study, 111In-DOTA-PR81 was prepared with radiochemical purity of >96%. High uptake of the complex in MUC1 + breast tumors compared to other nontarget organs shows that the radioimmunoconjugate is a beneficial agent for SPECT imaging of MUC1 + breast cancer. Human organs absorbed dose of the complex was estimated based on animals' data according to the RADAR and Spark et al. methods. The highest amounts of the absorbed dose are in the liver (0.384 mGy/MBq) and kidneys (0.245 mGy/MBq, respectively. 111In-DOTA-PR81 radioimmunoconjugate is a high potential agent for MUC1 + breast cancer SPECT imaging and estimated absorbed dose values could helpfully utilize for determining the maximum injectable dose.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
   References Top

1.
Clarke CA, Glaser SL, West DW, Ereman RR, Erdmann CA, Barlow JM, et al. Breast cancer incidence and mortality trends in an affluent population: Marin County, California, USA, 1990-1999. Breast Cancer Res 2002;4:R13.  Back to cited text no. 1
    
2.
Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 1988;263:12820-3.  Back to cited text no. 2
    
3.
Paknejad M, Rasaee MJ, Tehrani FK, Kashanian S, Mohagheghi MA, Omidfar K, et al. Production of monoclonal antibody, PR81, recognizing the tandem repeat region of MUC1 mucin. Hybrid Hybridomics 2003;22:153-8.  Back to cited text no. 3
    
4.
Salouti M, Babaei MH, Rajabi H, Rasaee Mj. Preparation and biological evaluation of (177)Lu conjugated PR81 for radioimmunotherapy of breast cancer. Nucl Med Biol 2011;38:849-55.  Back to cited text no. 4
    
5.
Salouti M, Rajabi H, Babaei MH, Rasaee MJ. Breast tumor targeting with (99m)Tc-HYNIC-PR81 complex as a new biologic radiopharmaceutical. Nucl Med Biol 2008;35:763-8.  Back to cited text no. 5
    
6.
Yousefnia H, Zolghadri S, Jalilian AR. Preparation and biodistribution assessment of 111In-BPAMD as a novel agent for bone SPECT imaging. Radiochim Acta 2015;103:653-61.  Back to cited text no. 6
    
7.
Yousefnia H, Zolghadri S. Human absorbed dose estimation of a new IN-111 imaging agent based on rat data. JPMS 2015;9:627-31.  Back to cited text no. 7
    
8.
Zhou Z, Wagh NK, Ogbomo SM, Shi W, Jia Y, Brusnahan SK, et al. Synthesis and in vitro and in vivo evaluation of hypoxia-enhanced 111In-bombesin conjugates for prostate cancer imaging. J Nucl Med 2013;54:1605-12.  Back to cited text no. 8
    
9.
Nijhof MW, Oyen WJ, van Kampen A, Claessens RA, van der Meer JW, Corstens FH. Evaluation of infections of the locomotor system with indium-111-labeled human IgG scintigraphy. J Nucl Med 1997;38:1300-5.  Back to cited text no. 9
    
10.
Lai J, Quadri SM, Borchardt PE, Harris L, Wucher R, Askew E, et al. Pharmacokinetics of radiolabeled polyclonal antiferritin in patients with Hodgkin's disease. Clin Cancer Res 1999;5:3315s-23s.  Back to cited text no. 10
    
11.
Stabin MG, Tagesson M, Thomas SR, Ljungberg M, Strand SE. Radiation dosimetry in nuclear medicine. Appl Radiat Isot 1999;50:73-87.  Back to cited text no. 11
    
12.
Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys 2003;85:294-310.  Back to cited text no. 12
    
13.
Yousefnia H, Jalilian AR, Zolghadri S, Mirzaei A, Bahrami-Samani A, Mirzaii M, et al. Development of 111In DOTMP for dosimetry of bone pain palliation agents. J Radioanal Nucl Chem 2015;304:911-6.  Back to cited text no. 13
    
14.
Alirezapour B, Rasaee MJ, Jalilian AR, Rajabifar S, Mohammadnejad J, Paknejad M, et al. Development of [64Cu]-DOTA-PR81 radioimmunoconjugate for MUC-1 positive PET imaging. Nucl Med Biol 2016;43:73-80.  Back to cited text no. 14
    
15.
IAEA-TECDOC-1401. Quantifying Uncertainty in Nuclear Analytical Measurements. Austria, Vienna: IAEA; 2004.  Back to cited text no. 15
    
16.
Sparks R, Aydogan B. Comparison of the Effectiveness of Some Common Animal Data Scaling Techniques in Estimating Human Radiation Dose. TN (United States): Oak Ridge Associated Universities; 1999.  Back to cited text no. 16
    
17.
Yousefnia H, Zolghadri S, Jalilian AR, Tajik M, Ghannadi-Maragheh M. Preliminary dosimetric evaluation of (166)Ho-TTHMP for human based on biodistribution data in rats. Appl Radiat Isot 2014;94:260-5.  Back to cited text no. 17
    
18.
Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023-7.  Back to cited text no. 18
    
19.
The 2007 recommendations of the international commission on radiological protection. ICRP publication 103. Ann ICRP 2007;37:1-332.  Back to cited text no. 19
    
20.
United States Pharmacopoeia 28, NF 23. Washington, D.C., Rockville, Md.: United States Pharmacopeia Convention, 2004. p. 1895.  Back to cited text no. 20
    
21.
Kesner AL, Hsueh WA, Czernin J, Padgett H, Phelps ME, Silverman DH. Radiation dose estimates for [18F] 5-fluorouracil derived from PET-based and tissue-based methods in rats. Mol Imaging Biol 2008;10:341-8.  Back to cited text no. 21
    
22.
Radiological Protection in Biomedical Research. ICRP Publication 62. Vol. 22. Elsevier Health Sciences: Annals of ICRP; 1992.  Back to cited text no. 22
    
23.
Vaez-Tehrani M, Zolghadri S, Yousefnia H, Afarideh H. Estimation of human absorbed dose for 166Ho-PAM: Comparison with 166Ho-DOTMP and 166Ho-TTHMP. Br J Radiol 2016;89:20160153.  Back to cited text no. 23
    
24.
Yousefnia H, Zolghadri S, Jalilian AR. Absorbed dose assessment of (177)Lu-zoledronate and (177)Lu-EDTMP for human based on biodistribution data in rats. J Med Phys 2015;40:102-8.  Back to cited text no. 24
[PUBMED]  [Full text]  
25.
Shanehsazzadeh S, Lahooti A, Yousefnia H, Geramifar P, Jalilian AR. Comparison of estimated human dose of (68)Ga-MAA with (99m) Tc-MAA based on rat data. Ann Nucl Med 2015;29:745-53.  Back to cited text no. 25
    
26.
Mankoff DA, Peterson LM, Tewson TJ, Link JM, Gralow JR, Graham MM, et al. [18F] fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 2001;42:679-84.  Back to cited text no. 26
    
27.
McCall K, Abbott A, Hu J, Cheng SC, Kravets S, Dubey S, et al. Report on the PET/CT image-based radiation dosimetry of 18FDHT in women, an imaging agent with new applications for evaluation of androgen receptor status in patients with metastatic breast cancer. J Nucl Med 2019;60:1630.  Back to cited text no. 27
    
28.
Gaykema SB, de Jong JR, Perik PJ, Brouwers AH, Schröder CP, Oude Munnink TH, et al. (111)In-trastuzumab scintigraphy in HER2-positive metastatic breast cancer patients remains feasible during trastuzumab treatment. Mol Imaging 2014;13:1-6.  Back to cited text no. 28
    
29.
Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, et al. 111In-pentetreotide scintigraphy: Procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010;37:1441-8.  Back to cited text no. 29
    


    Figures

  [Figure 1], [Figure 2], [Figure 3]
 
 
    Tables

  [Table 1], [Table 2], [Table 3]



 

Top
Print this article  Email this article
  

    

 
   Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Article in PDF (825 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
   Introduction
    Materials and Me...
    Results and Disc...
   Conclusions
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed60    
    Printed0    
    Emailed0    
    PDF Downloaded12    
    Comments [Add]    

Recommend this journal